nodes	percent_of_prediction	percent_of_DWPC	metapath
Anagrelide—Pollakiuria—Doxorubicin—testicular cancer	0.000751	0.000751	CcSEcCtD
Anagrelide—Haematuria—Epirubicin—testicular cancer	0.000747	0.000747	CcSEcCtD
Anagrelide—Dizziness—Ifosfamide—testicular cancer	0.000746	0.000746	CcSEcCtD
Anagrelide—Pharyngitis—Methotrexate—testicular cancer	0.000746	0.000746	CcSEcCtD
Anagrelide—Urinary tract disorder—Methotrexate—testicular cancer	0.000742	0.000742	CcSEcCtD
Anagrelide—Photosensitivity reaction—Doxorubicin—testicular cancer	0.000742	0.000742	CcSEcCtD
Anagrelide—Hepatobiliary disease—Epirubicin—testicular cancer	0.000741	0.000741	CcSEcCtD
Anagrelide—Weight increased—Doxorubicin—testicular cancer	0.00074	0.00074	CcSEcCtD
Anagrelide—Epistaxis—Epirubicin—testicular cancer	0.000739	0.000739	CcSEcCtD
Anagrelide—Urethral disorder—Methotrexate—testicular cancer	0.000737	0.000737	CcSEcCtD
Anagrelide—Weight decreased—Doxorubicin—testicular cancer	0.000736	0.000736	CcSEcCtD
Anagrelide—Sinusitis—Epirubicin—testicular cancer	0.000735	0.000735	CcSEcCtD
Anagrelide—Feeling abnormal—Etoposide—testicular cancer	0.000735	0.000735	CcSEcCtD
Anagrelide—Nausea—Dactinomycin—testicular cancer	0.000732	0.000732	CcSEcCtD
Anagrelide—Pneumonia—Doxorubicin—testicular cancer	0.000729	0.000729	CcSEcCtD
Anagrelide—Gastrointestinal pain—Etoposide—testicular cancer	0.000729	0.000729	CcSEcCtD
Anagrelide—Visual impairment—Methotrexate—testicular cancer	0.000724	0.000724	CcSEcCtD
Anagrelide—Vomiting—Ifosfamide—testicular cancer	0.000718	0.000718	CcSEcCtD
Anagrelide—Renal failure—Doxorubicin—testicular cancer	0.000713	0.000713	CcSEcCtD
Anagrelide—Rash—Ifosfamide—testicular cancer	0.000712	0.000712	CcSEcCtD
Anagrelide—Dermatitis—Ifosfamide—testicular cancer	0.000711	0.000711	CcSEcCtD
Anagrelide—Urticaria—Etoposide—testicular cancer	0.000708	0.000708	CcSEcCtD
Anagrelide—Haemoglobin—Epirubicin—testicular cancer	0.000707	0.000707	CcSEcCtD
Anagrelide—Rhinitis—Epirubicin—testicular cancer	0.000705	0.000705	CcSEcCtD
Anagrelide—Abdominal pain—Etoposide—testicular cancer	0.000705	0.000705	CcSEcCtD
Anagrelide—Body temperature increased—Etoposide—testicular cancer	0.000705	0.000705	CcSEcCtD
Anagrelide—Conjunctivitis—Doxorubicin—testicular cancer	0.000705	0.000705	CcSEcCtD
Anagrelide—Urinary tract infection—Doxorubicin—testicular cancer	0.000705	0.000705	CcSEcCtD
Anagrelide—Haemorrhage—Epirubicin—testicular cancer	0.000703	0.000703	CcSEcCtD
Anagrelide—Hepatitis—Epirubicin—testicular cancer	0.000703	0.000703	CcSEcCtD
Anagrelide—Eye disorder—Methotrexate—testicular cancer	0.000702	0.000702	CcSEcCtD
Anagrelide—Tinnitus—Methotrexate—testicular cancer	0.000701	0.000701	CcSEcCtD
Anagrelide—Hypoaesthesia—Epirubicin—testicular cancer	0.0007	0.0007	CcSEcCtD
Anagrelide—Asthenia—Cisplatin—testicular cancer	0.000698	0.000698	CcSEcCtD
Anagrelide—Pharyngitis—Epirubicin—testicular cancer	0.000698	0.000698	CcSEcCtD
Anagrelide—Cardiac disorder—Methotrexate—testicular cancer	0.000697	0.000697	CcSEcCtD
Anagrelide—Sweating—Doxorubicin—testicular cancer	0.000695	0.000695	CcSEcCtD
Anagrelide—Urinary tract disorder—Epirubicin—testicular cancer	0.000695	0.000695	CcSEcCtD
Anagrelide—Oedema peripheral—Epirubicin—testicular cancer	0.000693	0.000693	CcSEcCtD
Anagrelide—Haematuria—Doxorubicin—testicular cancer	0.000691	0.000691	CcSEcCtD
Anagrelide—Connective tissue disorder—Epirubicin—testicular cancer	0.000691	0.000691	CcSEcCtD
Anagrelide—Urethral disorder—Epirubicin—testicular cancer	0.000689	0.000689	CcSEcCtD
Anagrelide—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000686	0.000686	CcSEcCtD
Anagrelide—Epistaxis—Doxorubicin—testicular cancer	0.000684	0.000684	CcSEcCtD
Anagrelide—Sinusitis—Doxorubicin—testicular cancer	0.00068	0.00068	CcSEcCtD
Anagrelide—Visual impairment—Epirubicin—testicular cancer	0.000678	0.000678	CcSEcCtD
Anagrelide—Mediastinal disorder—Methotrexate—testicular cancer	0.000677	0.000677	CcSEcCtD
Anagrelide—Chills—Methotrexate—testicular cancer	0.000674	0.000674	CcSEcCtD
Anagrelide—Nausea—Ifosfamide—testicular cancer	0.00067	0.00067	CcSEcCtD
Anagrelide—Diarrhoea—Cisplatin—testicular cancer	0.000666	0.000666	CcSEcCtD
Anagrelide—Alopecia—Methotrexate—testicular cancer	0.000664	0.000664	CcSEcCtD
Anagrelide—Eye disorder—Epirubicin—testicular cancer	0.000657	0.000657	CcSEcCtD
Anagrelide—Tinnitus—Epirubicin—testicular cancer	0.000656	0.000656	CcSEcCtD
Anagrelide—Malnutrition—Methotrexate—testicular cancer	0.000654	0.000654	CcSEcCtD
Anagrelide—Haemoglobin—Doxorubicin—testicular cancer	0.000654	0.000654	CcSEcCtD
Anagrelide—Cardiac disorder—Epirubicin—testicular cancer	0.000653	0.000653	CcSEcCtD
Anagrelide—Rhinitis—Doxorubicin—testicular cancer	0.000652	0.000652	CcSEcCtD
Anagrelide—Hepatitis—Doxorubicin—testicular cancer	0.000651	0.000651	CcSEcCtD
Anagrelide—Haemorrhage—Doxorubicin—testicular cancer	0.000651	0.000651	CcSEcCtD
Anagrelide—Hypoaesthesia—Doxorubicin—testicular cancer	0.000648	0.000648	CcSEcCtD
Anagrelide—Pharyngitis—Doxorubicin—testicular cancer	0.000646	0.000646	CcSEcCtD
Anagrelide—Urinary tract disorder—Doxorubicin—testicular cancer	0.000643	0.000643	CcSEcCtD
Anagrelide—Oedema peripheral—Doxorubicin—testicular cancer	0.000641	0.000641	CcSEcCtD
Anagrelide—Asthenia—Etoposide—testicular cancer	0.00064	0.00064	CcSEcCtD
Anagrelide—Connective tissue disorder—Doxorubicin—testicular cancer	0.000639	0.000639	CcSEcCtD
Anagrelide—Urethral disorder—Doxorubicin—testicular cancer	0.000638	0.000638	CcSEcCtD
Anagrelide—Mediastinal disorder—Epirubicin—testicular cancer	0.000634	0.000634	CcSEcCtD
Anagrelide—Back pain—Methotrexate—testicular cancer	0.000633	0.000633	CcSEcCtD
Anagrelide—Chills—Epirubicin—testicular cancer	0.000631	0.000631	CcSEcCtD
Anagrelide—Pruritus—Etoposide—testicular cancer	0.000631	0.000631	CcSEcCtD
Anagrelide—Arrhythmia—Epirubicin—testicular cancer	0.000628	0.000628	CcSEcCtD
Anagrelide—Visual impairment—Doxorubicin—testicular cancer	0.000627	0.000627	CcSEcCtD
Anagrelide—Alopecia—Epirubicin—testicular cancer	0.000622	0.000622	CcSEcCtD
Anagrelide—Vomiting—Cisplatin—testicular cancer	0.000619	0.000619	CcSEcCtD
Anagrelide—Vision blurred—Methotrexate—testicular cancer	0.000617	0.000617	CcSEcCtD
Anagrelide—Rash—Cisplatin—testicular cancer	0.000614	0.000614	CcSEcCtD
Anagrelide—Dermatitis—Cisplatin—testicular cancer	0.000613	0.000613	CcSEcCtD
Anagrelide—Malnutrition—Epirubicin—testicular cancer	0.000612	0.000612	CcSEcCtD
Anagrelide—Diarrhoea—Etoposide—testicular cancer	0.00061	0.00061	CcSEcCtD
Anagrelide—Eye disorder—Doxorubicin—testicular cancer	0.000608	0.000608	CcSEcCtD
Anagrelide—Ill-defined disorder—Methotrexate—testicular cancer	0.000607	0.000607	CcSEcCtD
Anagrelide—Tinnitus—Doxorubicin—testicular cancer	0.000607	0.000607	CcSEcCtD
Anagrelide—Anaemia—Methotrexate—testicular cancer	0.000605	0.000605	CcSEcCtD
Anagrelide—Cardiac disorder—Doxorubicin—testicular cancer	0.000604	0.000604	CcSEcCtD
Anagrelide—Flatulence—Epirubicin—testicular cancer	0.000603	0.000603	CcSEcCtD
Anagrelide—Tension—Epirubicin—testicular cancer	0.000601	0.000601	CcSEcCtD
Anagrelide—Nervousness—Epirubicin—testicular cancer	0.000595	0.000595	CcSEcCtD
Anagrelide—Back pain—Epirubicin—testicular cancer	0.000592	0.000592	CcSEcCtD
Anagrelide—Malaise—Methotrexate—testicular cancer	0.00059	0.00059	CcSEcCtD
Anagrelide—Dizziness—Etoposide—testicular cancer	0.000589	0.000589	CcSEcCtD
Anagrelide—Muscle spasms—Epirubicin—testicular cancer	0.000589	0.000589	CcSEcCtD
Anagrelide—Mediastinal disorder—Doxorubicin—testicular cancer	0.000587	0.000587	CcSEcCtD
Anagrelide—Chills—Doxorubicin—testicular cancer	0.000584	0.000584	CcSEcCtD
Anagrelide—Arrhythmia—Doxorubicin—testicular cancer	0.000581	0.000581	CcSEcCtD
Anagrelide—Nausea—Cisplatin—testicular cancer	0.000578	0.000578	CcSEcCtD
Anagrelide—Vision blurred—Epirubicin—testicular cancer	0.000577	0.000577	CcSEcCtD
Anagrelide—Alopecia—Doxorubicin—testicular cancer	0.000575	0.000575	CcSEcCtD
Anagrelide—Cough—Methotrexate—testicular cancer	0.000571	0.000571	CcSEcCtD
Anagrelide—Ill-defined disorder—Epirubicin—testicular cancer	0.000568	0.000568	CcSEcCtD
Anagrelide—Convulsion—Methotrexate—testicular cancer	0.000567	0.000567	CcSEcCtD
Anagrelide—Vomiting—Etoposide—testicular cancer	0.000567	0.000567	CcSEcCtD
Anagrelide—Malnutrition—Doxorubicin—testicular cancer	0.000567	0.000567	CcSEcCtD
Anagrelide—Anaemia—Epirubicin—testicular cancer	0.000566	0.000566	CcSEcCtD
Anagrelide—Rash—Etoposide—testicular cancer	0.000562	0.000562	CcSEcCtD
Anagrelide—Dermatitis—Etoposide—testicular cancer	0.000562	0.000562	CcSEcCtD
Anagrelide—Headache—Etoposide—testicular cancer	0.000558	0.000558	CcSEcCtD
Anagrelide—Flatulence—Doxorubicin—testicular cancer	0.000558	0.000558	CcSEcCtD
Anagrelide—Chest pain—Methotrexate—testicular cancer	0.000557	0.000557	CcSEcCtD
Anagrelide—Myalgia—Methotrexate—testicular cancer	0.000557	0.000557	CcSEcCtD
Anagrelide—Arthralgia—Methotrexate—testicular cancer	0.000557	0.000557	CcSEcCtD
Anagrelide—Tension—Doxorubicin—testicular cancer	0.000556	0.000556	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000553	0.000553	CcSEcCtD
Anagrelide—Malaise—Epirubicin—testicular cancer	0.000552	0.000552	CcSEcCtD
Anagrelide—Discomfort—Methotrexate—testicular cancer	0.00055	0.00055	CcSEcCtD
Anagrelide—Nervousness—Doxorubicin—testicular cancer	0.00055	0.00055	CcSEcCtD
Anagrelide—Syncope—Epirubicin—testicular cancer	0.000549	0.000549	CcSEcCtD
Anagrelide—Back pain—Doxorubicin—testicular cancer	0.000548	0.000548	CcSEcCtD
Anagrelide—Muscle spasms—Doxorubicin—testicular cancer	0.000545	0.000545	CcSEcCtD
Anagrelide—Palpitations—Epirubicin—testicular cancer	0.000541	0.000541	CcSEcCtD
Anagrelide—Confusional state—Methotrexate—testicular cancer	0.000538	0.000538	CcSEcCtD
Anagrelide—Loss of consciousness—Epirubicin—testicular cancer	0.000538	0.000538	CcSEcCtD
Anagrelide—Cough—Epirubicin—testicular cancer	0.000534	0.000534	CcSEcCtD
Anagrelide—Vision blurred—Doxorubicin—testicular cancer	0.000534	0.000534	CcSEcCtD
Anagrelide—Convulsion—Epirubicin—testicular cancer	0.00053	0.00053	CcSEcCtD
Anagrelide—Infection—Methotrexate—testicular cancer	0.00053	0.00053	CcSEcCtD
Anagrelide—Nausea—Etoposide—testicular cancer	0.000529	0.000529	CcSEcCtD
Anagrelide—Hypertension—Epirubicin—testicular cancer	0.000529	0.000529	CcSEcCtD
Anagrelide—Ill-defined disorder—Doxorubicin—testicular cancer	0.000526	0.000526	CcSEcCtD
Anagrelide—Nervous system disorder—Methotrexate—testicular cancer	0.000524	0.000524	CcSEcCtD
Anagrelide—Anaemia—Doxorubicin—testicular cancer	0.000524	0.000524	CcSEcCtD
Anagrelide—Thrombocytopenia—Methotrexate—testicular cancer	0.000523	0.000523	CcSEcCtD
Anagrelide—Arthralgia—Epirubicin—testicular cancer	0.000521	0.000521	CcSEcCtD
Anagrelide—Chest pain—Epirubicin—testicular cancer	0.000521	0.000521	CcSEcCtD
Anagrelide—Myalgia—Epirubicin—testicular cancer	0.000521	0.000521	CcSEcCtD
Anagrelide—Skin disorder—Methotrexate—testicular cancer	0.000519	0.000519	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000518	0.000518	CcSEcCtD
Anagrelide—Hyperhidrosis—Methotrexate—testicular cancer	0.000516	0.000516	CcSEcCtD
Anagrelide—Discomfort—Epirubicin—testicular cancer	0.000515	0.000515	CcSEcCtD
Anagrelide—Malaise—Doxorubicin—testicular cancer	0.000511	0.000511	CcSEcCtD
Anagrelide—Dry mouth—Epirubicin—testicular cancer	0.00051	0.00051	CcSEcCtD
Anagrelide—Anorexia—Methotrexate—testicular cancer	0.000509	0.000509	CcSEcCtD
Anagrelide—Syncope—Doxorubicin—testicular cancer	0.000508	0.000508	CcSEcCtD
Anagrelide—Confusional state—Epirubicin—testicular cancer	0.000504	0.000504	CcSEcCtD
Anagrelide—Palpitations—Doxorubicin—testicular cancer	0.000501	0.000501	CcSEcCtD
Anagrelide—Oedema—Epirubicin—testicular cancer	0.0005	0.0005	CcSEcCtD
Anagrelide—Hypotension—Methotrexate—testicular cancer	0.000499	0.000499	CcSEcCtD
Anagrelide—Loss of consciousness—Doxorubicin—testicular cancer	0.000498	0.000498	CcSEcCtD
Anagrelide—Infection—Epirubicin—testicular cancer	0.000496	0.000496	CcSEcCtD
Anagrelide—Cough—Doxorubicin—testicular cancer	0.000494	0.000494	CcSEcCtD
Anagrelide—Shock—Epirubicin—testicular cancer	0.000492	0.000492	CcSEcCtD
Anagrelide—Convulsion—Doxorubicin—testicular cancer	0.000491	0.000491	CcSEcCtD
Anagrelide—Nervous system disorder—Epirubicin—testicular cancer	0.00049	0.00049	CcSEcCtD
Anagrelide—Thrombocytopenia—Epirubicin—testicular cancer	0.000489	0.000489	CcSEcCtD
Anagrelide—Hypertension—Doxorubicin—testicular cancer	0.000489	0.000489	CcSEcCtD
Anagrelide—Tachycardia—Epirubicin—testicular cancer	0.000488	0.000488	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000486	0.000486	CcSEcCtD
Anagrelide—Skin disorder—Epirubicin—testicular cancer	0.000485	0.000485	CcSEcCtD
Anagrelide—Hyperhidrosis—Epirubicin—testicular cancer	0.000483	0.000483	CcSEcCtD
Anagrelide—Insomnia—Methotrexate—testicular cancer	0.000483	0.000483	CcSEcCtD
Anagrelide—Arthralgia—Doxorubicin—testicular cancer	0.000482	0.000482	CcSEcCtD
Anagrelide—Chest pain—Doxorubicin—testicular cancer	0.000482	0.000482	CcSEcCtD
Anagrelide—Myalgia—Doxorubicin—testicular cancer	0.000482	0.000482	CcSEcCtD
Anagrelide—Paraesthesia—Methotrexate—testicular cancer	0.000479	0.000479	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000479	0.000479	CcSEcCtD
Anagrelide—Discomfort—Doxorubicin—testicular cancer	0.000477	0.000477	CcSEcCtD
Anagrelide—Anorexia—Epirubicin—testicular cancer	0.000476	0.000476	CcSEcCtD
Anagrelide—Dyspnoea—Methotrexate—testicular cancer	0.000476	0.000476	CcSEcCtD
Anagrelide—Somnolence—Methotrexate—testicular cancer	0.000475	0.000475	CcSEcCtD
Anagrelide—Dry mouth—Doxorubicin—testicular cancer	0.000472	0.000472	CcSEcCtD
Anagrelide—Dyspepsia—Methotrexate—testicular cancer	0.00047	0.00047	CcSEcCtD
Anagrelide—Hypotension—Epirubicin—testicular cancer	0.000467	0.000467	CcSEcCtD
Anagrelide—Confusional state—Doxorubicin—testicular cancer	0.000466	0.000466	CcSEcCtD
Anagrelide—Decreased appetite—Methotrexate—testicular cancer	0.000464	0.000464	CcSEcCtD
Anagrelide—Oedema—Doxorubicin—testicular cancer	0.000462	0.000462	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000461	0.000461	CcSEcCtD
Anagrelide—Fatigue—Methotrexate—testicular cancer	0.00046	0.00046	CcSEcCtD
Anagrelide—Infection—Doxorubicin—testicular cancer	0.000459	0.000459	CcSEcCtD
Anagrelide—Pain—Methotrexate—testicular cancer	0.000457	0.000457	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000455	0.000455	CcSEcCtD
Anagrelide—Shock—Doxorubicin—testicular cancer	0.000455	0.000455	CcSEcCtD
Anagrelide—Nervous system disorder—Doxorubicin—testicular cancer	0.000453	0.000453	CcSEcCtD
Anagrelide—Thrombocytopenia—Doxorubicin—testicular cancer	0.000453	0.000453	CcSEcCtD
Anagrelide—Insomnia—Epirubicin—testicular cancer	0.000452	0.000452	CcSEcCtD
Anagrelide—Tachycardia—Doxorubicin—testicular cancer	0.000451	0.000451	CcSEcCtD
Anagrelide—Skin disorder—Doxorubicin—testicular cancer	0.000449	0.000449	CcSEcCtD
Anagrelide—Paraesthesia—Epirubicin—testicular cancer	0.000449	0.000449	CcSEcCtD
Anagrelide—Hyperhidrosis—Doxorubicin—testicular cancer	0.000447	0.000447	CcSEcCtD
Anagrelide—Dyspnoea—Epirubicin—testicular cancer	0.000445	0.000445	CcSEcCtD
Anagrelide—Somnolence—Epirubicin—testicular cancer	0.000444	0.000444	CcSEcCtD
Anagrelide—Anorexia—Doxorubicin—testicular cancer	0.000441	0.000441	CcSEcCtD
Anagrelide—Feeling abnormal—Methotrexate—testicular cancer	0.00044	0.00044	CcSEcCtD
Anagrelide—Dyspepsia—Epirubicin—testicular cancer	0.00044	0.00044	CcSEcCtD
Anagrelide—Gastrointestinal pain—Methotrexate—testicular cancer	0.000437	0.000437	CcSEcCtD
Anagrelide—Decreased appetite—Epirubicin—testicular cancer	0.000434	0.000434	CcSEcCtD
Anagrelide—Hypotension—Doxorubicin—testicular cancer	0.000432	0.000432	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000431	0.000431	CcSEcCtD
Anagrelide—Fatigue—Epirubicin—testicular cancer	0.000431	0.000431	CcSEcCtD
Anagrelide—Constipation—Epirubicin—testicular cancer	0.000427	0.000427	CcSEcCtD
Anagrelide—Pain—Epirubicin—testicular cancer	0.000427	0.000427	CcSEcCtD
Anagrelide—Urticaria—Methotrexate—testicular cancer	0.000424	0.000424	CcSEcCtD
Anagrelide—Body temperature increased—Methotrexate—testicular cancer	0.000422	0.000422	CcSEcCtD
Anagrelide—Abdominal pain—Methotrexate—testicular cancer	0.000422	0.000422	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000421	0.000421	CcSEcCtD
Anagrelide—Insomnia—Doxorubicin—testicular cancer	0.000418	0.000418	CcSEcCtD
Anagrelide—Paraesthesia—Doxorubicin—testicular cancer	0.000415	0.000415	CcSEcCtD
Anagrelide—Dyspnoea—Doxorubicin—testicular cancer	0.000412	0.000412	CcSEcCtD
Anagrelide—Feeling abnormal—Epirubicin—testicular cancer	0.000412	0.000412	CcSEcCtD
Anagrelide—Somnolence—Doxorubicin—testicular cancer	0.000411	0.000411	CcSEcCtD
Anagrelide—Gastrointestinal pain—Epirubicin—testicular cancer	0.000409	0.000409	CcSEcCtD
Anagrelide—Dyspepsia—Doxorubicin—testicular cancer	0.000407	0.000407	CcSEcCtD
Anagrelide—Decreased appetite—Doxorubicin—testicular cancer	0.000402	0.000402	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000399	0.000399	CcSEcCtD
Anagrelide—Fatigue—Doxorubicin—testicular cancer	0.000399	0.000399	CcSEcCtD
Anagrelide—Urticaria—Epirubicin—testicular cancer	0.000397	0.000397	CcSEcCtD
Anagrelide—Pain—Doxorubicin—testicular cancer	0.000395	0.000395	CcSEcCtD
Anagrelide—Constipation—Doxorubicin—testicular cancer	0.000395	0.000395	CcSEcCtD
Anagrelide—Body temperature increased—Epirubicin—testicular cancer	0.000395	0.000395	CcSEcCtD
Anagrelide—Abdominal pain—Epirubicin—testicular cancer	0.000395	0.000395	CcSEcCtD
Anagrelide—Asthenia—Methotrexate—testicular cancer	0.000383	0.000383	CcSEcCtD
Anagrelide—Feeling abnormal—Doxorubicin—testicular cancer	0.000381	0.000381	CcSEcCtD
Anagrelide—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000378	0.000378	CcSEcCtD
Anagrelide—Pruritus—Methotrexate—testicular cancer	0.000378	0.000378	CcSEcCtD
Anagrelide—Urticaria—Doxorubicin—testicular cancer	0.000367	0.000367	CcSEcCtD
Anagrelide—Abdominal pain—Doxorubicin—testicular cancer	0.000365	0.000365	CcSEcCtD
Anagrelide—Body temperature increased—Doxorubicin—testicular cancer	0.000365	0.000365	CcSEcCtD
Anagrelide—Diarrhoea—Methotrexate—testicular cancer	0.000365	0.000365	CcSEcCtD
Anagrelide—Asthenia—Epirubicin—testicular cancer	0.000359	0.000359	CcSEcCtD
Anagrelide—Pruritus—Epirubicin—testicular cancer	0.000354	0.000354	CcSEcCtD
Anagrelide—Dizziness—Methotrexate—testicular cancer	0.000353	0.000353	CcSEcCtD
Anagrelide—Diarrhoea—Epirubicin—testicular cancer	0.000342	0.000342	CcSEcCtD
Anagrelide—Vomiting—Methotrexate—testicular cancer	0.000339	0.000339	CcSEcCtD
Anagrelide—Rash—Methotrexate—testicular cancer	0.000337	0.000337	CcSEcCtD
Anagrelide—Dermatitis—Methotrexate—testicular cancer	0.000336	0.000336	CcSEcCtD
Anagrelide—Headache—Methotrexate—testicular cancer	0.000334	0.000334	CcSEcCtD
Anagrelide—Asthenia—Doxorubicin—testicular cancer	0.000332	0.000332	CcSEcCtD
Anagrelide—Dizziness—Epirubicin—testicular cancer	0.00033	0.00033	CcSEcCtD
Anagrelide—Pruritus—Doxorubicin—testicular cancer	0.000327	0.000327	CcSEcCtD
Anagrelide—Vomiting—Epirubicin—testicular cancer	0.000318	0.000318	CcSEcCtD
Anagrelide—Nausea—Methotrexate—testicular cancer	0.000317	0.000317	CcSEcCtD
Anagrelide—Diarrhoea—Doxorubicin—testicular cancer	0.000316	0.000316	CcSEcCtD
Anagrelide—Rash—Epirubicin—testicular cancer	0.000315	0.000315	CcSEcCtD
Anagrelide—Dermatitis—Epirubicin—testicular cancer	0.000315	0.000315	CcSEcCtD
Anagrelide—Headache—Epirubicin—testicular cancer	0.000313	0.000313	CcSEcCtD
Anagrelide—Dizziness—Doxorubicin—testicular cancer	0.000306	0.000306	CcSEcCtD
Anagrelide—Nausea—Epirubicin—testicular cancer	0.000297	0.000297	CcSEcCtD
Anagrelide—Vomiting—Doxorubicin—testicular cancer	0.000294	0.000294	CcSEcCtD
Anagrelide—Rash—Doxorubicin—testicular cancer	0.000292	0.000292	CcSEcCtD
Anagrelide—Dermatitis—Doxorubicin—testicular cancer	0.000291	0.000291	CcSEcCtD
Anagrelide—Headache—Doxorubicin—testicular cancer	0.00029	0.00029	CcSEcCtD
Anagrelide—Nausea—Doxorubicin—testicular cancer	0.000275	0.000275	CcSEcCtD
